I last reviewed Danaher (DHR) in this February 1, 2024 post at which time the Q4 and FY2023 results had just been released. Prior to this post, I published Danaher Consistently Generates Strong Free Cash Flow and Danaher - Current Weakness Is A Buying Opportunity following the release of Q2 and Q3 results, respectively. In [...]
When I wrote my April 20, 2024 Intuitive Surgical (ISRG) post, shares were trading at ~$366. In that post, I note that it was my 15th largest holding when I completed my 2023 Year End FFJ Portfolio Review at which time shares were trading at ~$337. The appreciation in ISRG's share price coupled with some [...]
I try to identify great companies that, for whatever reason, appear to have temporarily fallen out of favor with investors. When I last added to my Blackstone (BX) exposure on May 9, 2023 @ ~$81.65, I was of the opinion that BX's share price was temporarily depressed for no justifiable reason. In contrast, the share [...]
When I last reviewed BlackRock (BLK) in this April 15 post, the most currently available financial information was for Q1 2024. I considered shares to be reasonably valued and disclosed the purchase of another 30 shares @ ~$770/share on April 12; this increased my BLK exposure to 160 shares in the FFJ Portfolio. In several [...]
There is no disputing that Nike (NKE) has experienced its fair share of challenges in recent years. Soft demand for sportswear in key markets and an increasingly competitive industry has resulted in lacklustre top line growth. In FY2020 and FY2024, for example, NKE reported a decline in YoY sales growth. On the Q4 2024 earnings [...]
My underlying reason for performing this 2024 Mid Year FFJ Portfolio Review is to get a high level overview of all our investments. I manage a total of 19 accounts held at two discount brokers. Unless I perform these reviews, I can not easily determine what percentage of our total holdings is held in each [...]
This FFJ Portfolio - June 2024 report recaps my investment activity during the month. In my June 11 FFJ Portfolio Adjustments Before Capital Gains Tax Changes Arrive, I disclose multiple changes to the FFJ Portfolio. After these changes, drawing a direct comparison with prior periods is of little value. I, therefore, am no longer providing [...]
I last reviewed Alimentation Couche-Tard (ATD.to) in this December 7, 2023 post. At the time, the most current financial information was for Q2 and YTD2024. We now have ATD's Q4 and FY2024 results which has prompted me to revisit this company. When I wrote my prior post, I held 1227 ATD shares in one of [...]
My analysis of Brown-Forman is accessible through my guest post at Dividend Power. When I wrote my December 13, 2016 Brown-Forman Corporation Stock Analysis: Enriching Life? Not Lately! post, the company's slogan was Enriching Life. Now, the company's slogan is Nothing Better. If Brown-Forman (BF) is talking about its investment performance, nothing could be further [...]
In my May 20 West Pharmaceutical (WST) post, I disclosed the purchase of an additional 100 shares @ ~$345.56 in the FFJ Portfolio on May 20 after listening to WST's presentation at BofA's Health Care Conference 2024. Nothing has materially changed following that purchase. WST's share price has, however, experienced subsequent weakness thus leading me [...]